Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds

Ocera Therapeutics, Inc. (OCRX): Venrock Healthcare Capital Patners Snapping Up Shares

Published on March 3, 2016 at 11:31 am by Meena Krishnamsetty in Hedge Funds
Page 1 of 18
Next >>

Anders Hove and Bong Koh’s VHCP Management disclosed a large increase in its Ocera Therapeutics (OCRX) stake. According to the latest 13F filings, Venrock had 700K shares of OCRX at the end of December. A new filing reveals an increase of almost 1.2 million shares in Venrock’s OCRX stake.

At Q4’s end, a total of 10 of the hedge funds tracked by Insider Monkey were long this stock, a change of 11% from the previous quarter. According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Great Point Partners, managed by Jeffrey Jay and David Kroin, holds the biggest position in Ocera Therapeutics Inc (NASDAQ:OCRX). Great Point Partners has a $6.1 million position in the stock, comprising 2.6% of its 13F portfolio. On Great Point Partners’s heels is QVT Financial, led by Daniel Gold, holding a $2.9 million position; 0.2% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors that are bullish include Israel Englander’s Millennium Management and Hal Mintz’s Sabby Capital.

As industrywide interest jumped, specific money managers were breaking ground themselves. Citadel Investment Group, managed by Ken Griffin, initiated the most outsized position in Ocera Therapeutics Inc (NASDAQ:OCRX). Citadel Investment Group had $0.1 million invested in the company at the end of the quarter.

Follow Anders Hove And Bong Koh's VHCP Management

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Venrock Healthcare Capital Partners 0 1,885,668 0 1,885,668 1,885,668 9.1%
VHCP Co-Investment Holdings 0 1,885,668 0 1,885,668 1,885,668 9.1%
Venrock Healthcare Capital Partners II 0 1,885,668 0 1,885,668 1,885,668 9.1%
VHCP Co-Investment Holdings II 0 1,885,668 0 1,885,668 1,885,668 9.1%
VHCP Management 0 1,885,668 0 1,885,668 1,885,668 9.1%
VHCP Management II 0 1,885,668 0 1,885,668 1,885,668 9.1%
Hove, Anders 0 1,885,668 0 1,885,668 1,885,668 9.1%
Koh, Bong 0 1,885,668 0 1,885,668 1,885,668 9.1%

Page 1 of 18 SEC Filing



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.  )*
 
 
Ocera Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
67552A108
(CUSIP Number)
February 23, 2016
(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

Follow Ocera Therapeutics Inc. (NASDAQ:OCRX)


Page 1 of 18
Next >>

Show more...Show less

Related Insider Monkey Articles
Connecture Inc (CNXR), Hyperion Therapeutics Inc (HPTX): Top 5 Healthcare Picks...Are Hedge Funds Losing Interest In Ocera Therapeutics Inc (OCRX)?
Jeffrey Ray's Great Point Partners Trims Its Stake In Alcobra Ltd (ADHD)